Abstract
Background It is important to investigate, diagnose and commence treatment for locally advanced and metastatic prostate cancer quickly to optimise treatment outcomes. Since the introduction of national 2-week wait and 31/62-day targets in the United Kingdom for investigation of suspected prostate cancer over 2 decades ago, the clinical pathway has become increasingly complex. This may lead to some patients with the most clinically significant disease having the rapidity of their diagnosis and commencement of treatment compromised by resource use in diagnosing less significant, or clinically insignificant, disease.
Methods We will conduct a retrospective review of timelines for diagnosis and commencement of treatment for all men referred to a tertiary unit for investigation of suspected prostate cancer on the 2-week wait pathway in a 3-month period in 2023. In parallel, we will introduce triaging of all new 2-week wait referrals in a prospective 3-month period, with a dedicated nurse navigator streamlining patients for the most rapid investigation and treatment, based on pre-specified risk criteria including PSA, pre-biopsy mpMRI findings including TNM staging, and histology results. We hypothesise that this bespoke triaging system, above and beyond the 2-week wait and 2022 Faster Diagnostic Pathway guidance issued by NHS England, will improve timings for investigation and commencement of treatment for the most clinically significant prostate cancer cases.
Conclusions The use of in-house criteria for triaging and stratification of the most clinically urgent and significant prostate cancer cases, identified by a nurse specialist navigator, may improve clinical outcomes for patients with greatest need for rapid prostate cancer imaging, diagnosis and treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have registered an actionable review of the entire 2-week wait and 28/62-day prostate cancer diagnosis and treatment pathway at our Institution (Oxford University Hospitals NHS Foundation Trust). This registered QIP (OUH reference number 8381) aims to allow all those engaged in the various multiple steps of the 2-week wait and 28/62-day pathway to triage the highest risk cases for the most rapid diagnosis and treatment, whilst simultaneously safeguarding against undue delay for lower-risk cases as an unintended consequence.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations
- ADT
- Androgen Deprivation Therapy
- ANP
- Advanced Nurse Practitioner
- BAUS
- British Association of Urological Surgeons
- CNS
- Clinical Nurse Specialist
- DRE
- Digital rectal Examination
- EAU
- European Association of Urology
- ECOG
- Eastern Cooperative Oncology Group
- LATP
- Local Anaesthetic TransPerineal
- MDT
- MultiDisciplinary Team
- mpMRI
- Multi-parametric Magnetic Resonance Imaging
- NHS
- National Health Service
- NICE
- National Institute for health and Care Excellence
- PI-RADS
- Prostate Imaging Reporting And Data System
- PRAGMATIC
- PRostate cancer diAGnosis and MAnagement – Triage In Clinical care pathway.
- PSA
- Prostate Specific Antigen
- PSAd
- Prostate Specific Antigen density
- PSMA PET CT
- Prostate Specific Membrane Antigen Positron Emission Tomography– Computed Tomography
- QIP
- Quality Improvement Project
- TNM
- Tumour, Nodes, Metastasis
- TRUS
- TransRectal Ultrasound
